Cargando…
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The randomized controlled trials were identified through systematic searches of electronic databases through February 10, 20...
Autores principales: | Yu, Su-Yeon, Koh, Dae-Hyup, Choi, Miyoung, Ryoo, Seungeun, Huh, Kyungmin, Yeom, Joon Sup, Yoon, Young Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037226/ https://www.ncbi.nlm.nih.gov/pubmed/35343397 http://dx.doi.org/10.1080/22221751.2022.2059405 |
Ejemplares similares
-
Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
por: Ryoo, Seungeun, et al.
Publicado: (2023) -
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019) -
Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2023) -
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020) -
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)